Integrin Receptor Antagonists

Integrin Receptor Antagonist

Colitis, Ulcerative

Crohn Disease

Enteritis

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Vedolizumab, an integrin receptor antagonist, is a humanized IgG<span class="Sub">1 </span>monoclonal antibody produced in Chinese hamster ovary cells that binds to the human α4β7 integrin. ENTYVIO has an approximate molecular weight of 147 kilodaltons.</p><div class="Section" data-sectioncode="42229-5"><a name="section-9.1"></a><p></p><p class="First"><span class="Italics Underline">Intravenous ENTYVIO</span></p><p>ENTYVIO (vedolizumab) for injection is supplied as a sterile, white to off-white, preservative-free, lyophilized cake for intravenous infusion. After reconstitution with 4.8 mL Sterile Water for Injection, USP, 0.9% Sodium Chloride Injection, USP, or Lactated Ringer's Injection, USP, the resulting concentration is 60 mg/mL with a deliverable volume of 5 mL (300 mg) and the resulting pH is approximately 6.3.</p><p>Each single-dose vial contains 300 mg vedolizumab, arginine hydrochloride (131.7 mg), histidine (23 mg), histidine monohydrochloride (21.4 mg), polysorbate 80 (3 mg), and sucrose (500 mg).</p></div><div class="Section" data-sectioncode="42229-5"><a name="section-9.2"></a><p></p><p class="First"><span class="Italics Underline">Subcutaneous ENTYVIO</span></p><p>ENTYVIO (vedolizumab) injection is supplied as a sterile, clear to moderately opalescent, colorless to slightly yellow, preservative-free solution for subcutaneous administration.</p><p>Each single-dose prefilled syringe or single-dose prefilled pen (ENTYVIO PEN) contains 108 mg vedolizumab, arginine hydrochloride (17.77 mg), citric acid monohydrate (0.18 mg), histidine (3.86 mg), histidine monohydrochloride (1.86 mg), polysorbate 80 (1.35 mg), sodium citrate dihydrate (4.71 mg) and Sterile Water for Injection, USP, at a pH of 6.5.</p></div></section>

Entyvio

vedolizumab

vedolizumab 300 MG Injection

vedolizumab 300 MG Injection [Entyvio]

0.68 ML vedolizumab 159 MG/ML Prefilled Syringe

0.68 ML vedolizumab 159 MG/ML Prefilled Syringe [Entyvio]

0.68 ML vedolizumab 159 MG/ML Auto-Injector

0.68 ML vedolizumab 159 MG/ML Auto-Injector [Entyvio]

Chartwell Pennsylvania, L.P.

Actemra

Afinitor

Alecensa

Alunbrig

Ayvakit

Bafiertam

Bosulif

Bratovi

Brukinsa

Bynfezia

Cabometyx

Calquence

Cometriq

Copiktra

Cosentyx

Cotellic

Dysport

Enbrel

Erivedge

Erleada

Farydak

Fotivda

Gavreto

Ibrance

Idhifa

Ilumya

Imbruvica

Inlyta

Inqovi

Inrebic

Iressa

Jakafi

Koselugo

Lonsurf

Lorbrena

Lyypraza

Mayzent

Mekinist

Mektovi

Nexavar

Nubeqa

Ocrevus

Odomzo

Piqray

Ponvory

Retevmo

Rutixan

Rozlytrek

Rubraca

Stelara

Stivarga

Sutent

Tabrecta

Tafinlar

Tagrisso

Talzenna

Tarceva

Targretin

Tasigna

Temodar

Tibsovo

Truseltiq

Tykerb

Tymlos

Venclexta

Vizimpro

Votrient

Vyndamax

Vyndaqel

Xalkori

Xolair

Xospata

Xpovio

Xtandi

Yonsa

Zelboraf

Zeposia

Zydelig

Zykadia

Entyvio | Chartwell Pennsylvania, L.P. | limited distribution

Does Entyvio have a limited distribution partnership with Chartwell Pennsylvania, L.P.?

Which health plans does Chartwell Pennsylvania, L.P. have contracts with?

Does Chartwell Pennsylvania, L.P. work closely with Entyvio and Takeda Pharmaceuticals America, Inc.?

Does Chartwell Pennsylvania, L.P. offer services for Entyvio patients?

What conditions does Chartwell Pennsylvania, L.P. support?

How does Chartwell Pennsylvania, L.P. help with insurance?